Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
29 participants
INTERVENTIONAL
2018-06-25
2020-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of the Non-invasive Brain Stimulation on the Speech Fluency Enhancement
NCT03990168
Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering
NCT02288598
Stuttering and Neuromodulation
NCT07222163
Stimulation of the Thalamus to Ameliorate Persistent Disfluency
NCT05641701
Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech
NCT05437159
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active tDCS and fluency training
Participants will receive anodal tDCS at 2milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
Anodal tDCS
20 minutes of 2mA anodal stimulation.
Fluency training
Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
Sham tDCS and fluency training
Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
Fluency training
Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
Sham tDCS
For sham stimulation, current is ramped up and back down over 30 seconds.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anodal tDCS
20 minutes of 2mA anodal stimulation.
Fluency training
Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
Sham tDCS
For sham stimulation, current is ramped up and back down over 30 seconds.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stuttering severity ranging from mild to very severe, specifically Stuttering Severity Instrument (SSI) total score of 20 (mild) or higher and stuttering rates of 3% or higher
* scores within 1 standard deviation of the norm on the standardized tests for the study
Exclusion Criteria
* other neurological conditions such as Tourette's syndrome or post-traumatic stress disorder
* taking any medications/drugs that affect brain function
* history of past or current mental illness for example, schizophrenia that may affect brain development and function
* history of serious medical or neurological illness such as epilepsy and Parkinson's disease
* history of closed head injury (e.g., concussion)
* history of reading disorders
* hearing loss
* taking any medication, prescription or non-prescription with any psychotropic effects at the time of the study
* metal or electronic implants such as cochlear implants, and pacemakers
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Michigan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emily O'Dell Garnett
Research Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emily O Garnett, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Michigan
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUM00134495
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.